• Biospecimen SolutionsPrecision Value & HealthCareers
    P_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGB
    • Clinical
      Trial Services
        • Overview
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

        • Global Clinical Trial Support –
            • North & South America –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Europe –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • APAC –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

        • Clinical Trial Management –
            • Study Start-up & Feasibility –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Project Management –
            • Patient Recruitment –
            • Personalized Clinical Trial Operations –
            • Biometrics –
            • Medical & Safety Monitoring –
            • Clinical Data Management –
            • Medical Writing –
        • Clinical Development Strategy –
            • Clinical Development Planning –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Strategies –
            • Cell & Gene Therapy Strategies –
            • CDx Regulatory and Market Access –
        • Clinical Trial Design –
            • Basket & Umbrella Trials –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Clinical Trials –
            • Master Protocol Trials –
            • Decentralized Clinical Trials
        • Biostatistics –
            • Statistical Consulting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Study Design –
            • Data Monitoring Committees –
            • CDISC Programming and Documentation –
            • eCTD Submissions –
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Training
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

    • Lab
      Services
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Specialty Lab Services Overview –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • EU Contract Research Organization –
        • Immune Monitoring –
            • Immune Monitoring by Flow Cytometry –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • Immune Cell Phenotyping by Epiontis ID –
            • Cytokine Profiling –
            • Gene Expression Profiling –
            • ELISpot and FluoroSpot –
            • Custom Assays –
        • Flow Cytometry –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • Genomics –
            • NanoString Assays –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • ddPCR –
            • qPCR –
            • NGS –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
        • Tissue & Liquid Biopsy –
            • ApoStream – CTC and Rare Cell Isolation for Liquid Biopsy
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • CTC / cfDNA / Exosome Analysis –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry –
            • Fluorescence In Situ Hybridisation (FISH) / ISH
            • Pathology Services –
            • NanoString Assays
        • Bioanalytical Testing –
            • Immunogenicity Testing –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • PK Assays –
            • ADA Assays –
            • MesoScale Discovery (MSD) Assays –
            • Quanterix SIMOA –
            • ELISA
        • Cytokine Analysis –
            • ELISA –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • MesoScale Discovery (MSD) Assays
            • Luminex –
            • Quanterix SIMOA
        • Preclinical Target and Biomarker Validation –
            • Cell Based Assays –
            • Target Expression – XpressWay Profiles –
            • Tissue Cross-Reactivity –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry (IHC)
        • Biospecimens
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

    • Data
      Sciences
        • Overview
            • BiostatisticsImage

              Biostatistics


              Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

              • Computational BiologyImage

                Computational Biology


                Domain experts from our QuartzBio team utilize integrated and harmonized data and tailored AI solutions to drive preclinical and clinical development, including patient stratification, signature development, predictive modeling of drug response, and MOA characterization.

        • Biostatistics
        • Clinical Data Management
        • Biometrics
        • QuartzBio –
            • Biomarker Data Management –
              • BiostatisticsImage

                Biostatistics


                Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

            • Virtual Sample Inventory Management –
    • Diagnostics
      & CDx
        • IVD and CDx Regulatory Affairs Consulting –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • COVID-19 & Viral Panel Assays –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Biospecimens Solutions 
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Diagnostic Market Access Services –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Companion Diagnostics
    • Therapeutic
      Areas
        • Overview
            • By Specialty Area
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Oncology and Immuno-Oncology
              • Oncology Clinical Trials
            • Rare & Orphan Disease
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Cell & Gene Therapy
              • Cell Therapy
              • Gene Therapy
              • Cell and Gene Therapy Manufacturing
            • CNS & Neuroscience
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • COVID-19
            • AutoImmune & Allergy
            • Pediatric
        • By Research Phase
        • Preclinical Development –
        • Early Phase Trials (I-IIa) –
        • Late Phase Trials (IIb-III) –
    • News &
      Insights
        • Blog –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Resources –
        • Thought Leadership –
        • News –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Events –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

    • About
      Us
        • Our Passion –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

        • Meet Our People –
        • Careers
        • Regulatory Information –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

    • Contact
      Us
    • Home
    • Characterizing a Central Switch of Immune Suppression: Monitoring Treg Cells in Clinical Studies
    Blog Clinical Research Insights Translational & Lab Insights
    Article

    Characterizing a Central Switch of Immune Suppression: Monitoring Treg Cells in Clinical Studies

    Written By Eva Raschke, PhD • December 13, 2022 • 8 min. read

    Regulatory T (Treg) cells play a critical role in suppressing the immune response, thereby maintaining immune homeostasis and self-tolerance. Dysregulation in Treg cell type, frequency, or function is implicated in a variety of conditions, including autoimmune disease and cancer. There is still much to learn about Treg effector functions and molecular mechanisms in both health and disease. Thus, the ability to identify, quantify and characterize these cells is essential.

    Role of Treg cells in the immune system

    Treg cells exert their regulatory effects via competition for growth factors, soluble factors, and inhibitory receptors. This variety of mechanisms translates into myriad approaches by which drugs can target and influence Treg cells to shift the balance of the immune system. It is also why Treg dysregulation is observed in so many disease indications (see Figure 1).

    Figure 1. Conditions characterized by Treg dysregulation

    Discovery of Treg cells

    Mouse models, genetic mapping, and cell isolation all played a role in the discovery of Treg cells. The first observations came from a mouse strain called “scurfy”, where X-linked mutations in the transcription factor Forkhead box P3 gene (FoxP3) were linked to pronounced autoimmune pathology.1 In 2001, it was suggested that FoxP3 gene mutations cause immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, the human equivalent of mouse scurfy syndrome.2

    Meanwhile, researchers found that transferring CD4+CD25- T cells into athymic nude mice resulted in evidence of autoimmune disease. Reconstitution of CD4+CD25+ cells prevented these developments in a time- and dose-dependent manner, suggesting these cells are important for immunologic self-tolerance.3

    Ultimately, CD4+CD25+ cells were found to be FoxP3+ Treg cells, with the following key observations:

    1. FoxP3 is the main transcription factor programming the development and function of Treg cells.4
    2. While FoxP3 might be necessary for identifying Treg cells, it is not sufficient as activated T cells may express FoxP3 transiently. Thus, identification of Treg cells using flow cytometry would require several protein markers used in parallel—CD4, CD25, FoxP3, and low levels of CD127.5
    3. Treg-specific demethylated region (TSDR), a marker based on the methylation status of the FoxP3 gene, specifically characterizes Treg cells without cross-reacting with activated T cells.6,7

    These last two observations led to two technological approaches that are now widely used to monitor Treg cells.

    Methods for monitoring Treg cells

    Currently, there are two primary approaches to monitoring Treg cells

    • Flow cytometry (protein-based). This approach uses fluorescent antibodies, usually targeted at surface markers, to label cells. For Tregs, the two main markers are CD4 and CD25. CD127 is commonly used as a negative marker and intracellular staining of FoxP3 is usually included as well.
    • Epigenetic cell counting (DNA-based). Precision for Medicine’s proprietary immune monitoring platform, Epiontis ID, uses the absence of genomic DNA methylation signals at the TSDR region of the FoxP3 gene to identify Treg cells. In this approach, the DNA within a biological sample is treated with bisulfite, which converts all unmethylated cytosines into uracils causing chemically-induced based mutations that affect base pairing. Subsequently, quantitative real-time polymerase chain reaction (PCR) is performed to detect and measure only DNA copies from Treg cells.
    Figure 2. Assay principle for epigenetic cell counting

    Epiontis ID is fully automated, highly standardized, and very robust and reproducible over time, so it can support on-study measurements and comparison of data across different studies or with pre-existing healthy subject data. As of Q3 2022, assays for 36 markers have been fully validated on this platform (see Figure 3).

    Figure 3. Validated assays for Epiontis ID

    Any combination of these markers can be put into a custom panel for immune monitoring applications. To date, the most commonly used assay is the FoxP3 assay for Treg cells, which has been used in more than 100 clinical studies. Studies have demonstrated that quantification of Treg cell number by epigenetic cell counting correlates well with flow cytometry (see Figure 4).8

    Figure 4. Quantification of Treg cell number by flow cytometry and epigenetic cell counting10
    Adapted from Baron U, et al. Sci Transl Med. 2018;10(452):eaan3508.

    Using Epiontis ID to monitor Treg cells: Case studies

    Case study 1: Autoimmune disease

    In autoimmune diseases, the immune system shifts to pro-inflammatory immune cell populations. In a recent phase 2 trial, patients with systemic lupus erythematosus (SLE) were treated with iberdomide, a cereblon ligand. Treatment response was measured using the SLE Responder Index and additional exploratory biomarker analysis was performed at baseline and weeks 4, 12, and 24 using both epigenetic immunophenotyping and flow cytometry.

    Epigenetic immunophenotyping showed that Treg frequency increased following treatment in a dose-dependent manner, while T follicular helper cells increased slightly and T helper 17 (Th17) cells remained stable throughout treatment (see Figure 5).9 This case study not only demonstrated how cell populations that can be challenging to measure by flow cytometry can be monitored with Epiontis ID, but also suggested a potential mechanism of action for how iberdomide induces immune tolerance.

    Figure 5. Changes in T cell populations in patients with SLE following treatment with iberdomide9Adapted from Merrill JT, et al. N Engl J Med. 2022;386(11):1034-1045.

    Case study 2: Cancer

    In cancer, the immune system often shifts to low inflammatory activity. A study published in Epigenetics in 2013 coined the term immunoCRIT, the ratio of suppressive Treg cells to total T cells, as a measure of immune tolerance. In this study, Epiontis ID was used to characterize Treg infiltration in tissue or tumor samples. It was found that that immunoCRIT is elevated in tumor samples and this elevation becomes more pronounced as the cancer progresses.10 Thus, epigenetic immunophenotyping could potentially be useful for setting thresholds for stratifying patient cohorts or predicting response to treatment.

    Case study 3: IPEX syndrome

    IPEX is caused by a mutation in the FoxP3 gene, while IPEX-like disease is a similar, sometimes less severe, condition that is not caused by FoxP3 mutations. In a study involving patients with IPEX and IPEX-like disease, Epiontis ID was used to measure the levels of Treg cells. Patients with IPEX were found to have high levels of TSDR demethylated cells that did not display a suppressive function due to the FoxP3 gene mutation. IPEX-like patients had low levels of TSDR demethylated cells, much lower than healthy subjects and somewhat lower than patients with other autoimmune diseases.

    Flow cytometric analysis is difficult in IPEX as FoxP3 protein levels vary by gene mutation. However, TSDR demethylation analysis using Epiontis ID, coupled with FoxP3 gene mutation analysis, may improve diagnostic accuracy and help to optimize treatment of patients with IPEX.

    Selecting the best approach for Treg monitoring

    When deciding which method of Treg monitoring is most appropriate for an immune monitoring project, researchers should consider the phase and size of the study, the cell types of interest, the sample type, and the timeline (see Figure 6).

    Figure 6. Selection criteria for flow cytometry and epigenetic immune monitoring

    In research, preclinical, and small early clinical studies, flow cytometry is usually recommended. As soon as human samples are introduced, Epiontis ID can be added for early bridging purposes. In large, multi-center, late-stage trials, Epiontis ID offers ease and cost-effectiveness as it can use frozen samples and does not require fresh blood or peripheral blood mononuclear cell (PBMC) processing. If specialty applications such as receptor occupancy or protein phosphorylation are required, flow cytometry is necessary.

    Flow cytometry would also be the only option for cell types that are not yet available with Epiontis ID, but certain cell types—such as Tregs and Th17 cells—are easier to measure epigenetically. It is also more feasible to measure blood and tissue in parallel using Epiontis ID. Finally, since Epiontis ID assays are fully validated and can be combined as necessary, there is no need to allocate time or resources to developing and validating a custom panel.

    Conclusion

    Both flow cytometry and epigenetic immunophenotyping can be used to monitor Treg cells in clinical studies. Understanding the limitations and advantages of each technology platform is essential for selecting the most appropriate approach for Treg cell monitoring based on study phase and size, key cell types of interest, and sample type. Given the vast diversity of Treg cells, future research will focus on the identification and validation of molecular markers for defining and differentiating among subtypes to better understand their complex roles in immunity and their potential as therapeutic targets.

    Explore our global immune monitoring services and solutions >

    References

    1. Russell WL, Russell LB, Gower JS. Exceptional inheritance of a sex-linked gene in the mouse explained on the basis that the X/O sexchromosome constitution is female. Proc Natl Acad Sci. 1959;45:554-560.

    2. Wildin RS, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27(1):18-20.

    3. Sakaguchi S, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-1164.

    4. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330-336.

    5. Liu W, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701-1711.

    6. Floess S, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5(2):e38.

    7. Baron U, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol. 2007;37(9):2378-2389.

    8. Baron U, et al. Epigenetic immune cell counting in human blood samples for immunodiagnostics. Sci Transl Med. 2018;10(452):eaan3508.

    9. Merrill JT, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med. 2022;386(11):1034-1045.

    10. Türbachova I, et al. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics. 2013;8(11):1226-1235.


    • Eva Raschke, PhD

      Eva Raschke, PhD serves as a subject matter expert for immune monitoring solutions at Precision for Medicine with a focus on the epigenetic immune monitoring technology Epiontis ID. She has supported the development, validation and clinical use of this technology platform in different roles since 2008. Eva obtained a Ph.D. in Molecular Biology from the Ludwig-Maximilians-University Munich.

    Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

    Visit the website
    Clinical Trial Services
    • Overview
    • Global Clinical Trial Support
    • Clinical Trial Management
    • Clinical Development Strategy
    • Clinical Trial Design
    • Biostatistics
    • Clinical Sample Management
    • Clinical Research Organization
    Specialty Lab Services
    • Overview
    • Immune Monitoring
    • Flow Cytometry
    • Genomics
    • Tissue & Liquid Biopsy
    • Bioanalytical Testing
    • Cytokine Analysis
    • Biospecimens
    • Sample Processing
    • Global Specimen Transport & Biostorage
    • Contract Research Organization
    • Bioanalysis
    • Neutralizing Antibody (NAb) Assays
    • PBMC Processing
    Data Sciences
    • Overview
    • Biostatistics
    • Clinical Data Management
    • Biometrics
    • QuartzBio
    • Virtual Sample Inventory Management
    Therapeutic Expertise
    • Overview
    • Preclinical Development
    • Early Phase Trials (I-IIa)
    • Late Phase Trials (IIb-III)
    • Oncology and Immuno-Oncology
    • Rare & Orphan Disease
    • Cell & Gene Therapy
    • Neurology
    • COVID-19
    • Autoimmune & Allergy
    • Pediatric
    • Companion Diagnostics
    About Us
    • Our Passion
    • Meet Our People
    • Careers
    • ESG Policy
    • Regulatory Information

    News & Insights
    • Publications
    • Case Studies
    • Thought Leadership
    • News
    • Events
    © 2023 Precision Medicine Group, LLC. All rights reserved. Privacy Policy    GDPR